Cyrus Biotechnology Presents Implementation of Biocomputing on the Cloud at the American Chemical Society Spring Meeting in San Francisco

SEATTLE, April 3, 2017 — Cyrus Biotechnology, Inc., a new biotechnology software company offering the most advanced protein modeling and design capabilities to the Biopharmaceutical, Synthetic Biology, Chemical, and Consumer Products industries is pleased to announce its participation to the American Chemical Society Spring Meeting in San Francisco on April 3rd, 2017.

Dr. Lucas Nivon, CEO of Cyrus Bio, will speak about Cyrus’s journey of deploying the Rosetta software on the cloud and share lessons learned. The Rosetta software, from the RosettaCommons, is the premier software platform for advanced computational protein engineering. It is a very complex software stack that requires years to learn in depth, is difficult to document, and is constantly in flux as new scientific features are created.

Cyrus has implemented the Rosetta stack on a public computing cloud, resulting in higher quality software with far higher performance in a secure multi-tenant model. R&D organizations can remove large capital expenditures, avoid over- or under-provisioning, and maximize scientific output.

Scripting or computing queues are no longer needed for structural biologists and biochemists who want to do protein design or modeling without having advanced computational skills.

Scientific computing is diverse, requires high performance and does not trivially extend to the cloud. It requires cloud-based systems architected specifically for scientific computing, using modern web technologies and frameworks, such as high performance web frontends and backend job provisioning.

In silico modeling and design of proteins is becoming increasingly relevant to the pharmaceutical industry, as investment in research, development and clinical trials of biologic therapeutics continue to grow. Cyrus Bench® software, and the underlying Rosetta software package, are already leveraged by many global pharmaceutical organizations and are at the nexus of this major trend. Cyrus customers can apply the most advanced and validated in silico protein engineering science through an intuitive user interface for:


  • Protein Structure Prediction (best overall performance at CASP and CAMEO)
  • Protein Stabilization (single point mutants, multiple point mutants, evolutionary redesign)
  • Protein / Protein Interface Design
  • Protein Design (modifications to function or structure)
  • Enzyme Optimization

Cyrus Bio wishes to thank Dr. Veerabahu Shanmugasundaram, one of the session’s organizers, for his kind invitation to speak at the Meeting.



Cyrus Biotechnology

Cyrus Biotechnology, Inc. is a new privately-held biotechnology software company offering protein modeling and design capabilities to the Biopharmaceutical, Chemical, Consumer Products and Synthetic Biology industries. Cyrus was founded in 2014 as a spin-out from the University of Washington, and offers Cyrus Bench®, a Software-as-a-Service (SaaS) platform for protein structure prediction, modeling, stabilization, engineering and design to accelerate discovery of Biologics and Small Molecules. Cyrus Bench® is based primarily on the Rosetta software package from Prof. David Baker’s lab at the University of Washington, along with associated software. Cyrus Bench® offers the world-leading protein structure prediction pipeline of Rosetta and SparksX, the top structure prediction software in the bi-annual CASP competition and the weekly CAMEO competition, as well as the only protein engineering software experimentally proven to design new proteins completely via software. Cyrus Bench® is based on over 15 years of biochemistry software development and over 400 published papers demonstrating experimental efficacy in vitro and in vivo.


NOTICE: The information contained in this document is dated as of January 10, 2017.  Cyrus Biotechnology, Inc. (the Company) disclaims any obligation to update such information after such date.  This document contains forward–looking statements reflecting the Company’s current expectations that necessarily involve risks and uncertainties.  Actual results and the timing of events may differ materially from those contained in such forward-looking statements due to a number of factors and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Share this post